TIL

Business Context and Reporting Period

Company: Instil Bio, Inc. (Nasdaq: TIL)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Instil Bio is a clinical-stage biopharmaceutical company. In August 2024, its subsidiary Axion Bio in-licensed two product candidates from ImmuneOnco Biopharmaceuticals (Shanghai) Inc.: AXN-2510/IMM2510 (a PD-L1xVEGF bispecific antibody) and AXN-27M/IMM27M (an anti-CTLA-4 monoclonal antibody). The company retains global rights excluding Greater China, where ImmuneOnco retains rights. Instil Bio has discontinued its previous cell therapy programs (CoStAR-TIL) to focus on these in-licensed assets.

Key Financial Metrics

Note: The company has no revenue from product sales. Operating expenses include $10.0 million in in-process research and development (IPR&D) charges related to the ImmuneOnco license and $7.5 million in restructuring and impairment charges.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $82 million (52%) from 2023 to 2024, primarily driven by a significant reduction in restructuring and impairment charges ($72.0 million in 2023 vs. $7.5 million in 2024) and lower research and development expenses due to the discontinuation of prior cell therapy programs.
• Strategic Pivot: The company shifted focus from its proprietary CoStAR-TIL cell therapy to the in-licensed AXN-2510/IMM2510 and AXN-27M/IMM27M assets, resulting in $10.0 million of IPR&D expense in 2024.
• Debt Refinancing: In December 2024, the company refinanced its construction loans with a new $85.6 million term loan bearing a fixed interest rate of 6.35% per annum, maturing in two years with a one-year extension option.
• Asset Monetization: The company's Tarzana, California manufacturing facility was leased to AstraZeneca in July 2024, generating $4.3 million in rental income in 2024 (compared to $0 in 2023).

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($115.1 million) are sufficient to fund operations beyond 2026. A potential sale of the Tarzana facility could extend this runway.
• Development Milestones: ImmuneOnco is conducting Phase 1 trials for AXN-2510/IMM2510 in China. As of January 2025, over 100 patients have been enrolled. Preliminary data showed partial responses in three patients. Instil Bio plans to initiate clinical development outside of China.
• Key Risks:
  • Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to advance clinical trials and commercialization.
  • Regulatory Uncertainty: Success depends on regulatory approval from the FDA and other authorities. Data from trials conducted in China may not be accepted by the FDA without additional U.S. trials.
  • Third-Party Dependence: The company relies on ImmuneOnco for manufacturing and clinical trial execution in China, and on third parties for future commercial manufacturing.
  • Restructuring: The company completed a significant restructuring in 2024, closing UK operations and reducing its workforce to 14 employees as of year-end.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $115.1 million cash balance against projected burn rates for the new clinical programs.
• Debt Covenants: Review the terms of the $85.6 million term loan, specifically the extension conditions and prepayment penalties.
• Asset Sale: Monitor the status of the potential sale of the Tarzana facility, which is currently leased to AstraZeneca.
• Clinical Data: Track the progression of ImmuneOnco's Phase 1 trials for AXN-2510/IMM2510 and the timeline for initiating U.S. trials.
• Restructuring Completion: Confirm the finalization of UK workforce reductions and associated liability payments.